<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155972</url>
  </required_header>
  <id_info>
    <org_study_id>179489</org_study_id>
    <nct_id>NCT02155972</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression</brief_title>
  <acronym>ALIGN</acronym>
  <official_title>The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Women's College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week randomized, double-blind placebo-controlled proof of concept study
      assessing the combination of a mood stabilizer + Align in the treatment of participants with
      a bipolar depressive episode. The study has two treatment arms: mood stabilizer plus placebo
      and mood stabilizer plus Align.

      The dose of mood stabilizer will be in accordance with clinical practice guidelines and the
      dose for Align will be 1 capsule per day as per appropriate product dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression has emerged as the major challenge for short- and long-term management of bipolar
      disorder; new treatments are needed to help control this illness. Studies indicate that
      probiotics in the stomach improves mood and reduces anxiety symptoms lending further support
      to the notion that probiotic bacteria positively influence emotional states. We propose to
      evaluate the effectiveness of the combination of mood stabilizer and Align, a probiotic as
      compared to mood stabilizer monotherapy.

      The primary goal of this feasibility study is to determine the safety and tolerability of
      Align as an add on to accepted monotherapy treatment in BD. Secondary Objective:1)To evaluate
      the effectiveness of the combination of mood stabilizer + Align compared to mood stabilizer
      monotherapy in treatment of BD. 2) to determine if Align +mood stabilizer combination will
      reduce anxiety symptoms.

      An 8-week randomized, double-blind placebo-controlled proof of concept study assessing the
      combination a mood stabilizer + Align in the treatment of patients with an bipolar depressive
      episode. The study has two treatment arms: mood stabilizer + placebo and mood stabilizer +
      Align. Participants will be assessed &amp; administered study scales at screening, baseline &amp;
      weeks 2,4,6 and 8. the dose for mood stabilizer will be in accordance with clinical practice
      guidelines and Align - 1 capsule/day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized to receive either ALIGN (probiotic) or Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of Align</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tolerability will be assessed using the Toronto Side Effect Scale (TSES). It is a 32-item instrument that is designed to establish incidence, frequency, and severity of central nervous system (CNS), gastrointestinal (GI), and sexual side effects. We will also assess the proportion of participants withdrawing from study due to inadequate control of depressive symptoms or treatment emergent mania</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effectiveness of the combination of mood stabilizer + Align</measure>
    <time_frame>8 weeks</time_frame>
    <description>This will be assessed through the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to the final visit (week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the combination of mood stabilizer + Align as compared to mood stabilizer monotherapy for participants with bipolar depression with respect to anxiety symptoms and global function/overall improvement</measure>
    <time_frame>8 weeks</time_frame>
    <description>Anxiety symptoms will be assessed by looking at the mean change in the State and Trait Anxiety Index (STAI) total score, quality of life will be assessed with the World Health Organization Quality of Life (WHO-QOL) scale and global functioning will be accessed via mean change in the following: Sheehan Disability Scale (SDS) score, the clinical global impressions (CGI) severity of illness score, the CGI-Improvement scale and the CGI Participant Assessment. All measures will be evaluated looking at change from baseline to week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium infantis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium infantis</intervention_name>
    <description>Probiotic supplement</description>
    <arm_group_label>Bifidobacterium infantis</arm_group_label>
    <other_name>ALIGN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed of the nature of the study and have agreed to and are able to read, review,
             and sign the informed consent form. The informed consent document will be written in
             English, therefore the volunteer must have the ability to read and communicate in
             English

          -  Male and Female participants 18 - 65 years of age ,inclusive, at the time of screening

          -  Demonstrates a diagnosis of bipolar depression (type I or II) according to the Mini
             International Neuropsychiatric interview (MINI)

          -  Is not hospitalized or institutionalized (outpatient) at the time of screening

          -  Have been on a stable (unchanged) and adequate dose of one of the permissible
             medications for at least 8 weeks prior to screening (lithium, valproate/divalproex,
             carbamazepine, lamotrigine, quetiapine/quetiapine XR, olanzapine, or risperidone)

          -  Demonstrates a maximum HAM-D score of 24 at screening and baseline visits

          -  Female participants Must:

        Not be breast feeding Not be pregnant or seeking to get pregnant during the course of this
        study. Be menopausal or using an acceptable method of birth control (implants, injectables,
        combined oral contraceptives, IUDs, sexual abstinence or a vasectomized partner)

        Exclusion Criteria:

          -  Demonstrates or reports a history of any of the DSM-IV criteria for classification of
             substance abuse/dependence disorders in the past year.

          -  Demonstrates the presence of active eating disorders, schizophrenia or schizoaffective
             disorder

          -  Demonstrates current psychotic symptoms

          -  Demonstrates a Young Mania Rating Scale (YMRS) score of &gt;12 at screening

          -  Demonstrates active suicidality based on the C-SSR scale

          -  Reports using any potent cytochrome P450 inhibitors (such as chloramphenicol,
             antifungal agents) during the 14 days prior to screening

          -  Reports a history of electroconvulsive therapy (ECT) during the 90 days prior to
             screening

          -  Reports using Align or any other probiotic supplement within the last year prior to
             screening

          -  Reports a history of allergic response(s) to components of Align (such as
             Bifidobacterioum), or any other related drug.

          -  Reports a presence or history of any medical conditions that would affect drug
             pharmacokinetics (gastrointestinal conditions such as chroris or colitus).

          -  Reports a history of any immunocompromising condition (such as HIV, lymphoma, patients
             undergoing long-term corticosteroid treatment)

          -  Currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal
             pain

          -  Reports use of other natural health products (in addition to probiotics) that affect
             depression (such as St. Johns Wart, Tryptophan) within the last 6 months prior to
             screening

          -  Reports frequent consumption of foods rich in / enriched with probiotics (e.g.
             yoghurt, drinks, e.t.c).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Taylor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asem M Bala, Msc</last_name>
    <phone>4163513732</phone>
    <phone_ext>2301</phone_ext>
    <email>asem.bala@wchospital.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women's college Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valerie Taylor, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan WI, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010 Dec;139(6):2102-2112.e1. doi: 10.1053/j.gastro.2010.06.063. Epub 2010 Jun 27.</citation>
    <PMID>20600016</PMID>
  </reference>
  <reference>
    <citation>Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011 Mar;23(3):187-92. doi: 10.1111/j.1365-2982.2010.01664.x.</citation>
    <PMID>21303428</PMID>
  </reference>
  <reference>
    <citation>Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun. 2010 Jan;24(1):9-16. doi: 10.1016/j.bbi.2009.05.058. Epub 2009 May 28. Review.</citation>
    <PMID>19481599</PMID>
  </reference>
  <reference>
    <citation>Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009 May;6(5):306-14. doi: 10.1038/nrgastro.2009.35. Review.</citation>
    <PMID>19404271</PMID>
  </reference>
  <reference>
    <citation>Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004 Jul 1;558(Pt 1):263-75. Epub 2004 May 7.</citation>
    <PMID>15133062</PMID>
  </reference>
  <reference>
    <citation>Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011 Mar;23(3):255-64, e119. doi: 10.1111/j.1365-2982.2010.01620.x. Epub 2010 Nov 5.</citation>
    <PMID>21054680</PMID>
  </reference>
  <reference>
    <citation>Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52. doi: 10.1073/pnas.1010529108. Epub 2011 Jan 31.</citation>
    <PMID>21282636</PMID>
  </reference>
  <reference>
    <citation>Lyte M, Li W, Opitz N, Gaykema RP, Goehler LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium. Physiol Behav. 2006 Oct 30;89(3):350-7. Epub 2006 Aug 2.</citation>
    <PMID>16887154</PMID>
  </reference>
  <reference>
    <citation>Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun. 2005 Jul;19(4):334-44.</citation>
    <PMID>15944073</PMID>
  </reference>
  <reference>
    <citation>Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16050-5. doi: 10.1073/pnas.1102999108. Epub 2011 Aug 29.</citation>
    <PMID>21876150</PMID>
  </reference>
  <reference>
    <citation>Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 Jun;59(6):530-7.</citation>
    <PMID>12044195</PMID>
  </reference>
  <reference>
    <citation>Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003 Mar;60(3):261-9.</citation>
    <PMID>12622659</PMID>
  </reference>
  <reference>
    <citation>Gitlin MJ, Mintz J, Sokolski K, Hammen C, Altshuler LL. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. J Clin Psychiatry. 2011 May;72(5):692-7. doi: 10.4088/JCP.09m05291gre. Epub 2010 Jun 29.</citation>
    <PMID>20673560</PMID>
  </reference>
  <reference>
    <citation>Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE Jr, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003 Jun;64(6):680-90; quiz 738-9.</citation>
    <PMID>12823083</PMID>
  </reference>
  <reference>
    <citation>Post RM, Leverich GS, Nolen WA, Kupka RW, Altshuler LL, Frye MA, Suppes T, McElroy S, Keck P, Grunze H, Walden J; Stanley Foundation Bipolar Network. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord. 2003 Dec;5(6):396-406. Review.</citation>
    <PMID>14636363</PMID>
  </reference>
  <reference>
    <citation>Joffe RT, MacQueen GM, Marriott M, Trevor Young L. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 2004 Feb;6(1):62-6.</citation>
    <PMID>14996142</PMID>
  </reference>
  <reference>
    <citation>Gaykema RP, Goehler LE, Lyte M. Brain response to cecal infection with Campylobacter jejuni: analysis with Fos immunohistochemistry. Brain Behav Immun. 2004 May;18(3):238-45.</citation>
    <PMID>15050651</PMID>
  </reference>
  <reference>
    <citation>Goehler LE, Park SM, Opitz N, Lyte M, Gaykema RP. Campylobacter jejuni infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. Brain Behav Immun. 2008 Mar;22(3):354-66. Epub 2007 Oct 24.</citation>
    <PMID>17920243</PMID>
  </reference>
  <reference>
    <citation>Li W, Dowd SE, Scurlock B, Acosta-Martinez V, Lyte M. Memory and learning behavior in mice is temporally associated with diet-induced alterations in gut bacteria. Physiol Behav. 2009 Mar 23;96(4-5):557-67. doi: 10.1016/j.physbeh.2008.12.004. Epub 2008 Dec 24.</citation>
    <PMID>19135464</PMID>
  </reference>
  <reference>
    <citation>Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 2009 Nov 23;1(1):19. doi: 10.1186/1757-4749-1-19.</citation>
    <PMID>19930635</PMID>
  </reference>
  <reference>
    <citation>Verdu EF. Probiotics effects on gastrointestinal function: beyond the gut? Neurogastroenterol Motil. 2009 May;21(5):477-80. doi: 10.1111/j.1365-2982.2009.01297.x.</citation>
    <PMID>19432946</PMID>
  </reference>
  <reference>
    <citation>Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol. 2006 Mar;40(3):264-9. Review.</citation>
    <PMID>16633134</PMID>
  </reference>
  <reference>
    <citation>Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005 Jan;257(1):78-92. Review.</citation>
    <PMID>15606379</PMID>
  </reference>
  <reference>
    <citation>Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007 Nov;56(11):1522-8. Epub 2007 Mar 5. Erratum in: Gut. 2008 Apr;57(4):560.</citation>
    <PMID>17339238</PMID>
  </reference>
  <reference>
    <citation>Eutamene H, Bueno L. Role of probiotics in correcting abnormalities of colonic flora induced by stress. Gut. 2007 Nov;56(11):1495-7.</citation>
    <PMID>17938427</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008 Dec;43(2):164-74. doi: 10.1016/j.jpsychires.2008.03.009. Epub 2008 May 5.</citation>
    <PMID>18456279</PMID>
  </reference>
  <reference>
    <citation>Girard SA, Bah TM, Kaloustian S, Lada-Moldovan L, Rondeau I, Tompkins TA, Godbout R, Rousseau G. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br J Nutr. 2009 Nov;102(10):1420-5. doi: 10.1017/S0007114509990766. Epub 2009 Jun 29.</citation>
    <PMID>19563693</PMID>
  </reference>
  <reference>
    <citation>Rao AV, Bested AC, Beaulne TM, Katzman MA, Iorio C, Berardi JM, Logan AC. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009 Mar 19;1(1):6. doi: 10.1186/1757-4749-1-6.</citation>
    <PMID>19338686</PMID>
  </reference>
  <reference>
    <citation>Logan AC, Katzman M. Major depressive disorder: probiotics may be an adjuvant therapy. Med Hypotheses. 2005;64(3):533-8.</citation>
    <PMID>15617861</PMID>
  </reference>
  <reference>
    <citation>Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009 Mar 1;29(5):508-18. doi: 10.1111/j.1365-2036.2008.03911.x. Epub 2008 Dec 2.</citation>
    <PMID>19053980</PMID>
  </reference>
  <reference>
    <citation>Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol. 1999 Sep;35(2):146-55.</citation>
    <PMID>10461128</PMID>
  </reference>
  <reference>
    <citation>Bailey MT, Lubach GR, Coe CL. Prenatal stress alters bacterial colonization of the gut in infant monkeys. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):414-21.</citation>
    <PMID>15085020</PMID>
  </reference>
  <reference>
    <citation>Tannock GW, Savage DC. Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect Immun. 1974 Mar;9(3):591-8.</citation>
    <PMID>4593471</PMID>
  </reference>
  <reference>
    <citation>Suzuki K, Harasawa R, Yoshitake Y, Mitsuoka T. Effects of crowding and heat stress on intestinal flora, body weight gain, and feed efficiency of growing rats and chicks. Nihon Juigaku Zasshi. 1983 Jun;45(3):331-8.</citation>
    <PMID>6632469</PMID>
  </reference>
  <reference>
    <citation>O'Mahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry. 2009 Feb 1;65(3):263-7. doi: 10.1016/j.biopsych.2008.06.026. Epub 2008 Aug 23.</citation>
    <PMID>18723164</PMID>
  </reference>
  <reference>
    <citation>Goncharova GI, Liz'ko NN, Liannaia AM, Shilov VM, Spitsa TI. [Bifidobacterium flora status of cosmonauts before and after completing space flights]. Kosm Biol Aviakosm Med. 1981;15(3):14-8. Russian.</citation>
    <PMID>7289537</PMID>
  </reference>
  <reference>
    <citation>Klooker TK, Braak B, Painter RC, de Rooij SR, van Elburg RM, van den Wijngaard RM, Roseboom TJ, Boeckxstaens GE. Exposure to severe wartime conditions in early life is associated with an increased risk of irritable bowel syndrome: a population-based cohort study. Am J Gastroenterol. 2009 Sep;104(9):2250-6. doi: 10.1038/ajg.2009.282. Epub 2009 Jun 9.</citation>
    <PMID>19513027</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald P, Cassidy Eugene M, Clarke G, Scully P, Barry S, Quigley Eamonn MM, Shanahan F, Cryan J, Dinan Timothy G. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil. 2008 Dec;20(12):1291-7. doi: 10.1111/j.1365-2982.2008.01195.x. Epub 2008 Sep 24.</citation>
    <PMID>18823288</PMID>
  </reference>
  <reference>
    <citation>Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002 Apr;122(4):1140-56. Review.</citation>
    <PMID>11910364</PMID>
  </reference>
  <reference>
    <citation>Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther. 2003 Jan-Feb;10(1):61-7. Review.</citation>
    <PMID>12522523</PMID>
  </reference>
  <reference>
    <citation>Marks DM, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, Masand PS. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry. 2008;10(5):368-75.</citation>
    <PMID>19158975</PMID>
  </reference>
  <reference>
    <citation>Creed F, Ratcliffe J, Fernandes L, Palmer S, Rigby C, Tomenson B, Guthrie E, Read N, Thompson DG; North of England IBS Research Group. Outcome in severe irritable bowel syndrome with and without accompanying depressive, panic and neurasthenic disorders. Br J Psychiatry. 2005 Jun;186:507-15.</citation>
    <PMID>15928362</PMID>
  </reference>
  <reference>
    <citation>O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 Mar;128(3):541-51.</citation>
    <PMID>15765388</PMID>
  </reference>
  <reference>
    <citation>Hamilton-Miller JMT. Probiotics in the Management of Irritable Bowel Syndrome: A Review of Clinical Trials. Microbial Ecology in Health &amp; Disease 2001;13:212-216</citation>
  </reference>
  <reference>
    <citation>Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904.</citation>
    <PMID>12656692</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687-96.</citation>
    <PMID>16185307</PMID>
  </reference>
  <reference>
    <citation>Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005 Sep 1;22(5):387-94.</citation>
    <PMID>16128676</PMID>
  </reference>
  <reference>
    <citation>Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. Clin Nutr. 2005 Dec;24(6):925-31. Epub 2005 Jul 27.</citation>
    <PMID>16051399</PMID>
  </reference>
  <reference>
    <citation>Bauserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005 Aug;147(2):197-201. Erratum in: J Pediatr. 2014 Oct;165(4):878. Bausserman, Melissa [corrected to Bauserman, Melissa].</citation>
    <PMID>16126049</PMID>
  </reference>
  <reference>
    <citation>McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003 Jul;52(7):975-80.</citation>
    <PMID>12801954</PMID>
  </reference>
  <reference>
    <citation>Duke K, Murphy S, Smith M. Probiotic performance in IBD is not uniform: a multi-strain comparison in the lymphocyte transfer model of enterocolitis. Gastroenterology. 2004;126:A283-A284.</citation>
  </reference>
  <reference>
    <citation>Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009 Aug;70(8):1078-90. doi: 10.4088/JCP.08r04505. Epub 2009 Jun 2. Review.</citation>
    <PMID>19497250</PMID>
  </reference>
  <reference>
    <citation>Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009 Aug;116(3):214-7. doi: 10.1016/j.jad.2008.12.001. Epub 2009 Feb 28.</citation>
    <PMID>19251324</PMID>
  </reference>
  <reference>
    <citation>Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ. Cytokine levels in euthymic bipolar patients. J Affect Disord. 2010 Nov;126(3):458-62. doi: 10.1016/j.jad.2010.04.027.</citation>
    <PMID>20537397</PMID>
  </reference>
  <reference>
    <citation>Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009 May;12(4):447-58. doi: 10.1017/S1461145708009310. Epub 2008 Sep 4.</citation>
    <PMID>18771602</PMID>
  </reference>
  <reference>
    <citation>Padmos RC, Van Baal GC, Vonk R, Wijkhuijs AJ, Kahn RS, Nolen WA, Drexhage HA. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch Gen Psychiatry. 2009 Sep;66(9):957-65. doi: 10.1001/archgenpsychiatry.2009.116.</citation>
    <PMID>19736352</PMID>
  </reference>
  <reference>
    <citation>Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience. 2010 Nov 10;170(4):1179-88. doi: 10.1016/j.neuroscience.2010.08.005. Epub 2010 Aug 6.</citation>
    <PMID>20696216</PMID>
  </reference>
  <reference>
    <citation>Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003 Sep 17;290(11):1517-9. Erratum in: JAMA. 2004 Jan 14;291(2):186.</citation>
    <PMID>13129995</PMID>
  </reference>
  <reference>
    <citation>Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9.</citation>
    <PMID>444788</PMID>
  </reference>
  <reference>
    <citation>Spielberger CD. Manual for the State-Trait Anxiety Inventory. Corsini Encyclopedia of Psychology. 1. Palo Alto, CA: Consulting Psychologists Press; 1983</citation>
  </reference>
  <reference>
    <citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35.</citation>
    <PMID>728692</PMID>
  </reference>
  <reference>
    <citation>Guy W. Global Impression Scale. ECDEU Assessment Manual for Psychopharmacology-Revised. 1976.</citation>
  </reference>
  <reference>
    <citation>Arbuckle R, Frye MA, Brecher M, Paulsson B, Rajagopalan K, Palmer S, Degl' Innocenti A. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Res. 2009 Jan 30;165(1-2):163-74. doi: 10.1016/j.psychres.2007.11.018. Epub 2008 Nov 29.</citation>
    <PMID>19042030</PMID>
  </reference>
  <reference>
    <citation>Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004 Mar;13(2):299-310.</citation>
    <PMID>15085902</PMID>
  </reference>
  <reference>
    <citation>Bartram AK, Lynch MD, Stearns JC, Moreno-Hagelsieb G, Neufeld JD. Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end illumina reads. Appl Environ Microbiol. 2011 Jun;77(11):3846-52. doi: 10.1128/AEM.02772-10. Epub 2011 Apr 1. Erratum in: Appl Environ Microbiol. 2011 Aug;77(15):5569.</citation>
    <PMID>21460107</PMID>
  </reference>
  <reference>
    <citation>American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50.</citation>
    <PMID>11958165</PMID>
  </reference>
  <reference>
    <citation>Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003 Jun;17(2):149-73; discussion 147.</citation>
    <PMID>12870562</PMID>
  </reference>
  <reference>
    <citation>Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry. 2004 May;38(5):280-305. Review.</citation>
    <PMID>15144505</PMID>
  </reference>
  <reference>
    <citation>Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry. 2004 Apr;65(4):571-9. Review.</citation>
    <PMID>15119923</PMID>
  </reference>
  <reference>
    <citation>Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005 Jul;66(7):870-86.</citation>
    <PMID>16013903</PMID>
  </reference>
  <reference>
    <citation>Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr. 2011 Sep;33(3):268-74.</citation>
    <PMID>21971780</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Women's College Hospital</investigator_affiliation>
    <investigator_full_name>Valerie Taylor</investigator_full_name>
    <investigator_title>Psychiatrist in Chief</investigator_title>
  </responsible_party>
  <keyword>Bipolar</keyword>
  <keyword>Depression</keyword>
  <keyword>Probiotic</keyword>
  <keyword>ALIGN</keyword>
  <keyword>HAMD</keyword>
  <keyword>STAI</keyword>
  <keyword>YMRS</keyword>
  <keyword>CGI</keyword>
  <keyword>SDS</keyword>
  <keyword>WHOQOL-BREF</keyword>
  <keyword>C-SSRS</keyword>
  <keyword>TSES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

